/EMBC
EMBC Stock - Embecta Corp.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$11.75+0.34%
+$0.04 (+0.34%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.27
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+112.8%upside
Target: $25.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EMBC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.63 – $11.87
TARGET (TP)$25.00
STOP LOSS$10.81
RISK/REWARD1:14.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.06
52W High$21.23
52W Low$9.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.08B | $1.12B | $1.12B | $1.13B | $1.17B |
| Gross Profit | $676.80M | $735.20M | $749.90M | $774.90M | $800.00M |
| Gross Margin | 62.6% | 65.5% | 66.9% | 68.6% | 68.7% |
| Operating Income | $242.10M | $166.80M | $221.50M | $309.60M | $492.00M |
| Net Income | $95.40M | $78.30M | $70.40M | $223.60M | $414.80M |
| Net Margin | 8.8% | 7.0% | 6.3% | 19.8% | 35.6% |
| EPS | $1.64 | $1.36 | $1.23 | $3.92 | $7.31 |
Company Overview
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
17%
Hold / Neutral
4
67%
Sell / Underperform
1
17%
Analyst Consensus🔴 Bearish
1 Bullish5 Neutral/Bearish
Price Targets
$25
Average Target
↑ 108.5% Upside
Now
$15
Low
$25
Average
$33
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 10th 2025 | Mizuho | Initiation | Neutral | $15 |
| December 2nd 2024 | Morgan Stanley | Upgrade | Equal Weight | $20← $13 |
| November 27th 2024 | BTIG Research | Upgrade | Buy | $26 |
| October 20th 2023 | Wolfe Research | Initiation | Peer Perform | - |
| January 6th 2023 | Morgan Stanley | Downgrade | Underweight | $28 |
| September 8th 2022 | BTIG Research | Initiation | Neutral | - |
| August 1st 2022 | Morgan Stanley | Initiation | Equal Weight | $33 |
| June 21st 2022 | BofA Securities | Initiation | Underperform | $25 |
Earnings History & Surprises
EMBCBeat Rate
93%
Last 14 quarters
Avg Surprise
+44.4%
EPS vs Estimate
Beats / Misses
13/1
Last 12 quarters
Latest EPS
$0.50
Q4 2025
EPS Surprise History
Q1 24
+35.6%
$0.61vs$0.45
Q2 24
+55.8%
$0.67vs$0.43
Q3 24
+54.2%
$0.74vs$0.48
Q4 24
+25.0%
$0.45vs$0.36
Q1 25
+44.4%
$0.65vs$0.45
Q2 25
+6.1%
$0.70vs$0.66
Q3 25
+146.2%
$1.12vs$0.46
Q4 25
-28.6%
$0.50vs$0.70
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $0.67 | — | — | — |
Q4 2025 | Nov 25, 2025 | $0.70 | $0.50 | -28.6% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $0.46 | $1.12 | +146.2% | ✓ BEAT |
Q2 2025 | May 9, 2025 | $0.66 | $0.70 | +6.1% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $0.45 | $0.65 | +44.4% | ✓ BEAT |
Q4 2024 | Nov 26, 2024 | $0.36 | $0.45 | +25.0% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $0.48 | $0.74 | +54.2% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.43 | $0.67 | +55.8% | ✓ BEAT |
Q1 2024 | Feb 9, 2024 | $0.45 | $0.61 | +35.6% | ✓ BEAT |
Q4 2023 | Nov 21, 2023 | $0.42 | $0.59 | +40.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.46 | $0.69 | +50.0% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $0.50 | $0.75 | +50.0% | ✓ BEAT |
Q1 2023 | Feb 14, 2023 | $0.52 | $0.96 | +84.6% | ✓ BEAT |
Q1 2023 | Feb 14, 2023 | — | $0.96 | — | — |
Q4 2022 | Dec 20, 2022 | $0.67 | $0.73 | +9.0% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $0.87 | $1.30 | +49.4% | ✓ BEAT |
Q2 2022 | May 13, 2022 | — | $1.38 | — | — |
Q1 2022 | Mar 16, 2022 | — | $1.73 | — | — |
Q4 2021 | Nov 14, 2021 | — | $1.70 | — | — |
Latest News
Embecta shares are trading lower after the company reported worse-than-expected Q4 financial results.
📉 NegativeBenzinga•Nov 25, 2025, 02:09 PM•Also:
Embecta Sees FY2026 Adj EPS $2.80-$3.00 vs $2.89 Est; Sees Sales $1.071B-$1.093B vs $1.082B Est
➖ NeutralBenzinga•Nov 25, 2025, 11:32 AM•Also:
Embecta Q4 2025 Adj. EPS $0.50 Misses $0.54 Estimate, Sales $264.000M Miss $265.685M Estimate
📉 NegativeBenzinga•Nov 25, 2025, 11:31 AM•Also:
Embecta Devdatt Kurdikar To Become Chairman Of Board
➖ NeutralBenzinga•Nov 17, 2025, 10:08 PM•Also:
Embecta Makes Largest Humanitarian Commitment Since Spinoff, Donating 15 Million Diabetes Injection Devices To Direct Relief On World Diabetes Day
📈 PositiveBenzinga•Nov 14, 2025, 11:31 AM•Also:
BTIG Reiterates Buy on Embecta, Maintains $25 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 09:58 AM•Also:
Frequently Asked Questions about EMBC
What is EMBC's current stock price?
Embecta Corp. (EMBC) is currently trading at $11.75 per share. The stock has moved +0.34% today.
What is the analyst price target for EMBC?
The average analyst price target for EMBC is $25.00, based on 1 analyst.
What sector is Embecta Corp. in?
Embecta Corp. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is EMBC's market cap?
Embecta Corp. has a market capitalization of $0.69 billion, making it a small-cap company.
Does EMBC pay dividends?
No, Embecta Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAQST
Aquestive Therapeutics, Inc.
$5.80
Mkt Cap: $0.6B
CDNA
CareDx, Inc
$19.45
Mkt Cap: $1.0B
EBS
Emergent BioSolutions Inc.
$12.42
Mkt Cap: $0.7B
EVH
Evolent Health, Inc.
$3.99
Mkt Cap: $0.5B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
MYGN
Myriad Genetics, Inc.
$6.55
Mkt Cap: $0.6B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
PSNL
Personalis, Inc.
$8.55
Mkt Cap: $0.8B
SIGA
SIGA Technologies, Inc.
$6.27
Mkt Cap: $0.4B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to EMBC for comparison